Lefty inhibitors belong to a distinct class of chemical compounds known for their pivotal role in regulating embryonic development and cell differentiation. These inhibitors are closely associated with the transforming growth factor-beta (TGF-β) superfamily of signaling molecules. To understand Lefty inhibitors, it's essential to appreciate their role within the intricate process of embryogenesis. During early development, Lefty inhibitors play a fundamental role in establishing the body plan of an organism. They are known for their function in maintaining symmetry and axis formation, a critical step in the early stages of embryonic development. Lefty inhibitors act as antagonists to certain signaling pathways within the TGF-β superfamily, exerting their influence by interfering with the signaling molecules involved. Specifically, they counteract the activity of Nodal, an important TGF-β member, which plays a key role in specifying the left-right axis in vertebrates. By doing so, Lefty inhibitors help ensure that the developing embryo forms with appropriate bilateral symmetry, preventing developmental abnormalities and ensuring the proper organization of vital organs.
Lefty inhibitors can be broadly classified into two isoforms: Lefty-1 and Lefty-2. Both isoforms exhibit similar mechanisms of action, working as negative regulators by binding to Nodal and inhibiting its signaling. This function is crucial for maintaining the balance of the Nodal pathway, preventing excessive or inappropriate signaling that could lead to developmental defects. Lefty inhibitors are a prime example of the delicate checks and balances that govern embryonic development. Their presence ensures the precise orchestration of signaling pathways, guaranteeing that an organism's body plan and symmetry are established correctly during its early stages of development. Understanding the mechanisms of Lefty inhibitors is not only essential for developmental biology but also holds potential implications for various fields of science and medicine, shedding light on the intricacies of cell signaling and differentiation.
VER TAMBIÉN ....
Items 1 to 10 of 15 total
Mostrar:
Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
---|---|---|---|---|---|---|
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
El nintedanib es un inhibidor de la tirosina cinasa que actúa sobre múltiples receptores, como el VEGFR, el FGFR y el PDGFR, inhibiendo las vías de la angiogénesis y la fibrosis. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
El imatinib inhibe la tirosina quinasa BCR-ABL, impidiendo la señalización aberrante en la leucemia mieloide crónica (LMC) y los tumores del estroma gastrointestinal (GIST). | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Este compuesto inhibe ampliamente la transcripción y podría reducir la expresión de numerosos genes, entre ellos LEFTY. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
El sorafenib se dirige a las quinasas RAF y VEGFR, interrumpiendo las vías MAPK y VEGF, que intervienen en el crecimiento y la propagación de las células. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
El erlotinib inhibe la tirosina quinasa EGFR, bloqueando las vías de señalización que promueven el crecimiento y la división celular. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Un inhibidor de la traducción de proteínas que podría reducir la síntesis de proteínas LEFTY. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
El sunitinib inhibe el VEGFR, el PDGFR y otras quinasas, interfiriendo en la angiogénesis y la proliferación de células tumorales, y se utiliza principalmente en el carcinoma de células renales. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
El gefitinib es un inhibidor de la tirosina quinasa EGFR, que detiene el crecimiento y la división de las células al interrumpir las vías de señalización impulsadas por el EGFR. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
El dasatinib se dirige contra BCR-ABL y otras quinasas, suprimiendo la proliferación de las células leucémicas, y se utiliza principalmente para la leucemia mieloide crónica (LMC). | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
Dada la interacción entre las señales Wnt y TGF-β, inhibidores como XAV-939 o ICG-001 podrían modular indirectamente la expresión o la actividad de LEFTY. |